At present, there are two approved and marketed EGF-R antibodies in regulated markets which posted sales of more than US$ 2.
The report includes a compilation of currently active projects in development of EGF-R targeting antibodies for treatment of inflammatory and autoimmune diseases.
Several antibodies targeting EGF-R and small molecules inhibiting the EGF-R tyrosine kinase have been approved and are used for treatment of colorectal cancer, squamous cell cancer of the head & neck or pancreatic cancer, respectively.
Competitor Analysis: EGF-R Agonists and Antagonists" includes a compilation of current active projects in research and development of molecules targeting the EGF receptor.
The pipeline of novel EGF-R targeting molecules is rather full and includes novel antibody as well as vaccine approaches and small molecules with a broader inhibition profile.
In addition, the report lists company-specific R&D pipelines of EGF-R targeting small molecules, antibodies, proteins, cells and vaccines.
Corporate EGF-R Agonist and Antagonist R&D Pipelines
A drug candidate, SU5271, has been selected that is a potent inhibitor of EGF-R signalling, and a license has been signed with Zeneca Ltd.
Psoriatic lesions are caused by the hyperproliferation of keratinocytes, and work by SUGEN and others has demonstrated that EGF-R signalling is required for the growth of keratinocytes.